Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature

Nishihori, Taiga; El-Asmar, Jessica; Shah, Bijal; Hussaini, Mohammad; Komrokji, Rami; List, Alan F.; Anasetti, Claudio; Kharfan‐Dabaja, Mohamed A.

doi:10.1038/bmt.2015.168

Cited by 5 publications

(3 citation statements)

References 18 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to current clinical practice standards, bone marrow donors are evaluated for general health, but not for any apparent and/or occult comorbid conditions such as constitutional chromosomal aberration(s) and/or other cancer-predisposing genetic conditions. Some donors have been reported to carry constitutional chromosomal aberration(s), such as karyotype of 47,XXY or 47,XXY, inversions involving chromosome(s) 3, 9, 10 and 12, trisomy 8, Robertsonian translocation(s), and/or other balanced reciprocal translocation(s) [8,26]. These chromosomal aberrations are mostly detected after transplant, and the same and/or evolved chromosomal aberrations were detected in the recipients.…”

Section: Discussionmentioning

confidence: 99%

Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review

Gu¹,

Wang²,

Tang³

et al. 2020

OBM Transplantation

View full text Add to dashboard Cite

Donor cell-derived leukaemia (DCL) is an uncommon complication of allogeneic hematopoietic stem cell transplantation (HSCT). DCL might represent up to 5% of the post-HSCT disease relapses, but case numbers reported in the literature might underestimate the frequency. The leukemogenesis of DCL is not well understood due to the limited numbers of cases reported and lack of detailed molecular genetic information from recipients and donors. Although many theories have been proposed for leukemogenesis of DCL, the underlying molecular genetic mechanism are likely heterogeneous. Here we report a case of donor cell-derived acute myeloid leukaemia with 3q26.2 involvement/MECOM rearrangement and chromosome 20q deletion. We also reviewed the literature of previously described DCL cases, and we discussed the risk factors that might be important to the onset of DCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review

Gu¹,

Wang²,

Tang³

et al. 2020

OBM Transplantation

View full text Add to dashboard Cite

show abstract

“…Although a causative mutation was not identified, this case may provide an insight into the aetiology of LHS. The transmission of genetic abnormalities via allogeneic haematopoietic stem cell is not unprecedented, 6 although other explanations are possible. These include engraftment of cells with congenital defects, engraftment of autoimmune effector cells, and pathogen transmission.…”

Section: Figurementioning

confidence: 99%

Possible transmission of Laugier–Hunziker syndrome by allogeneic peripheral blood stem cell transplantation

Steele

Hill²,

Cross

et al. 2020

Clin Exp Dermatol

View full text Add to dashboard Cite

show abstract

“…Kiss et al reported 3 donor-transmitted hematologic malignancies in 99 allogeneic HCTs (3%) in a 1-year period in a single institution in which bone marrow aspirates are performed routinely as part of pretransplantation assessment of all potential donors age >16 years, and all 3 donors were age >40 years [22]. A recent single-center study reported 4 allogeneic HCT recipients in whom donor-derived constitutional chromosomal aberrations were identified during post-transplantation evaluation [23]. Table 2 summarizes the donor-derived cytogenetic changes/malignancies reported to the NMDP between 2000 and 2015 in which follow-up information on the donor was available.…”

Section: Donor-derived Constitutional Abnormalities In Stem Cell Recimentioning

confidence: 99%

Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality

Dias

Al‐Kali

Dyke

et al. 2017

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation (HCT) is an important treatment for many severe hematologic disorders; however, HCT can be associated with significant complications, including organ toxicity, graft-versus-host disease, and relapse. Another serious, but rare, complication is the transmission of hematologic and nonhematologic diseases from the donor to the recipient. With older donors, the risk of an abnormality may be increased. Here we describe the transmission of an inversion 3 constitutional cytogenetic abnormality from an unrelated donor to a recipient, and review the clinical implications of the discovery of donor-derived constitutional cytogenetic abnormalities.

show abstract

Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature

Cited by 5 publications

References 18 publications

Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review

Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review

Possible transmission of Laugier–Hunziker syndrome by allogeneic peripheral blood stem cell transplantation

Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality

Contact Info

Product

Resources

About